3D-PHAD™ A80040 (Previously 699852) Monophosphoryl 3-Deacyl Lipid A (Synthetic)Pat No. 9,241,988

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

The highly pure MPLA analog, 3D-PHAD™, provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS. While comparable to bacterial MPLA and other synthetic MPLA analogs at eliciting an immune response in a liposomal adjuvant system (see bar graph), 3D-PHAD™ is less pyrogenic than its bacterial-derived mimic. Extensive preclinical testing with 3D-PHAD™ demonstrated equivalency to PHAD™, and human trials have been scheduled for launch. 3D-PHAD™ is protected under Pat No. 9,241,988. Licensing opportunities are available for vaccine or immunotherapy commercialization.

Stimulatory effect of PHAD™, 3D-PHAD™, and 3D(6-acyl)-PHAD™ on macrophages. Macrophage cell line J774 cells were cultured with Avanti PHAD™, 3D-PHAD™, or 3D(6-acyl)-PHAD™ for 24hrs. IL-12 levels in supernatants were measured by sandwich ELISA.